Dose finding of 3′deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose
The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Dalla Rosa, Luciana [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling - Samra, Yara A. ELSEVIER, 2020, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:85 ; year:2015 ; pages:21-28 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.micpath.2015.05.005 |
|---|
| Katalog-ID: |
ELV023724099 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV023724099 | ||
| 003 | DE-627 | ||
| 005 | 20230625141635.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.micpath.2015.05.005 |2 doi | |
| 028 | 5 | 2 | |a GBVA2015014000005.pica |
| 035 | |a (DE-627)ELV023724099 | ||
| 035 | |a (ELSEVIER)S0882-4010(15)00086-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Dalla Rosa, Luciana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dose finding of 3′deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose |
| 264 | 1 | |c 2015transfer abstract | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model. | ||
| 520 | |a The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model. | ||
| 650 | 7 | |a Adenosine |2 Elsevier | |
| 650 | 7 | |a Toxicity |2 Elsevier | |
| 650 | 7 | |a Trypanosomiasis |2 Elsevier | |
| 650 | 7 | |a Cordycepin |2 Elsevier | |
| 650 | 7 | |a Pentostatin |2 Elsevier | |
| 700 | 1 | |a Da Silva, Aleksandro S. |4 oth | |
| 700 | 1 | |a Oliveira, Camila B. |4 oth | |
| 700 | 1 | |a Gressler, Lucas T. |4 oth | |
| 700 | 1 | |a Arnold, Caroline B. |4 oth | |
| 700 | 1 | |a Baldissera, Matheus D. |4 oth | |
| 700 | 1 | |a Sagrillo, Michele |4 oth | |
| 700 | 1 | |a Sangoi, Manuela |4 oth | |
| 700 | 1 | |a Moresco, Rafael |4 oth | |
| 700 | 1 | |a Mendes, Ricardo E. |4 oth | |
| 700 | 1 | |a Weiss, Paulo E. |4 oth | |
| 700 | 1 | |a Miletti, Luiz C. |4 oth | |
| 700 | 1 | |a Monteiro, Silvia G. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Samra, Yara A. ELSEVIER |t Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling |d 2020 |g Amsterdam [u.a.] |w (DE-627)ELV00536194X |
| 773 | 1 | 8 | |g volume:85 |g year:2015 |g pages:21-28 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.micpath.2015.05.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.38 |j Pharmakologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 85 |j 2015 |h 21-28 |g 8 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
r l d rl rld |
|---|---|
| matchkey_str |
dallarosalucianadasilvaaleksandrosolivei:2015----:oeidno3exaeoiendoyoomcnoteramnotyaooavnine |
| hierarchy_sort_str |
2015transfer abstract |
| bklnumber |
44.38 |
| publishDate |
2015 |
| allfields |
10.1016/j.micpath.2015.05.005 doi GBVA2015014000005.pica (DE-627)ELV023724099 (ELSEVIER)S0882-4010(15)00086-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ PHARM DE-84 fid 44.38 bkl Dalla Rosa, Luciana verfasserin aut Dose finding of 3′deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose 2015transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model. The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model. Adenosine Elsevier Toxicity Elsevier Trypanosomiasis Elsevier Cordycepin Elsevier Pentostatin Elsevier Da Silva, Aleksandro S. oth Oliveira, Camila B. oth Gressler, Lucas T. oth Arnold, Caroline B. oth Baldissera, Matheus D. oth Sagrillo, Michele oth Sangoi, Manuela oth Moresco, Rafael oth Mendes, Ricardo E. oth Weiss, Paulo E. oth Miletti, Luiz C. oth Monteiro, Silvia G. oth Enthalten in Elsevier Samra, Yara A. ELSEVIER Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling 2020 Amsterdam [u.a.] (DE-627)ELV00536194X volume:85 year:2015 pages:21-28 extent:8 https://doi.org/10.1016/j.micpath.2015.05.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.38 Pharmakologie VZ AR 85 2015 21-28 8 045F 610 |
| spelling |
10.1016/j.micpath.2015.05.005 doi GBVA2015014000005.pica (DE-627)ELV023724099 (ELSEVIER)S0882-4010(15)00086-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ PHARM DE-84 fid 44.38 bkl Dalla Rosa, Luciana verfasserin aut Dose finding of 3′deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose 2015transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model. The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model. Adenosine Elsevier Toxicity Elsevier Trypanosomiasis Elsevier Cordycepin Elsevier Pentostatin Elsevier Da Silva, Aleksandro S. oth Oliveira, Camila B. oth Gressler, Lucas T. oth Arnold, Caroline B. oth Baldissera, Matheus D. oth Sagrillo, Michele oth Sangoi, Manuela oth Moresco, Rafael oth Mendes, Ricardo E. oth Weiss, Paulo E. oth Miletti, Luiz C. oth Monteiro, Silvia G. oth Enthalten in Elsevier Samra, Yara A. ELSEVIER Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling 2020 Amsterdam [u.a.] (DE-627)ELV00536194X volume:85 year:2015 pages:21-28 extent:8 https://doi.org/10.1016/j.micpath.2015.05.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.38 Pharmakologie VZ AR 85 2015 21-28 8 045F 610 |
| allfields_unstemmed |
10.1016/j.micpath.2015.05.005 doi GBVA2015014000005.pica (DE-627)ELV023724099 (ELSEVIER)S0882-4010(15)00086-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ PHARM DE-84 fid 44.38 bkl Dalla Rosa, Luciana verfasserin aut Dose finding of 3′deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose 2015transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model. The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model. Adenosine Elsevier Toxicity Elsevier Trypanosomiasis Elsevier Cordycepin Elsevier Pentostatin Elsevier Da Silva, Aleksandro S. oth Oliveira, Camila B. oth Gressler, Lucas T. oth Arnold, Caroline B. oth Baldissera, Matheus D. oth Sagrillo, Michele oth Sangoi, Manuela oth Moresco, Rafael oth Mendes, Ricardo E. oth Weiss, Paulo E. oth Miletti, Luiz C. oth Monteiro, Silvia G. oth Enthalten in Elsevier Samra, Yara A. ELSEVIER Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling 2020 Amsterdam [u.a.] (DE-627)ELV00536194X volume:85 year:2015 pages:21-28 extent:8 https://doi.org/10.1016/j.micpath.2015.05.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.38 Pharmakologie VZ AR 85 2015 21-28 8 045F 610 |
| allfieldsGer |
10.1016/j.micpath.2015.05.005 doi GBVA2015014000005.pica (DE-627)ELV023724099 (ELSEVIER)S0882-4010(15)00086-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ PHARM DE-84 fid 44.38 bkl Dalla Rosa, Luciana verfasserin aut Dose finding of 3′deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose 2015transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model. The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model. Adenosine Elsevier Toxicity Elsevier Trypanosomiasis Elsevier Cordycepin Elsevier Pentostatin Elsevier Da Silva, Aleksandro S. oth Oliveira, Camila B. oth Gressler, Lucas T. oth Arnold, Caroline B. oth Baldissera, Matheus D. oth Sagrillo, Michele oth Sangoi, Manuela oth Moresco, Rafael oth Mendes, Ricardo E. oth Weiss, Paulo E. oth Miletti, Luiz C. oth Monteiro, Silvia G. oth Enthalten in Elsevier Samra, Yara A. ELSEVIER Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling 2020 Amsterdam [u.a.] (DE-627)ELV00536194X volume:85 year:2015 pages:21-28 extent:8 https://doi.org/10.1016/j.micpath.2015.05.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.38 Pharmakologie VZ AR 85 2015 21-28 8 045F 610 |
| allfieldsSound |
10.1016/j.micpath.2015.05.005 doi GBVA2015014000005.pica (DE-627)ELV023724099 (ELSEVIER)S0882-4010(15)00086-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ PHARM DE-84 fid 44.38 bkl Dalla Rosa, Luciana verfasserin aut Dose finding of 3′deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose 2015transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model. The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model. Adenosine Elsevier Toxicity Elsevier Trypanosomiasis Elsevier Cordycepin Elsevier Pentostatin Elsevier Da Silva, Aleksandro S. oth Oliveira, Camila B. oth Gressler, Lucas T. oth Arnold, Caroline B. oth Baldissera, Matheus D. oth Sagrillo, Michele oth Sangoi, Manuela oth Moresco, Rafael oth Mendes, Ricardo E. oth Weiss, Paulo E. oth Miletti, Luiz C. oth Monteiro, Silvia G. oth Enthalten in Elsevier Samra, Yara A. ELSEVIER Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling 2020 Amsterdam [u.a.] (DE-627)ELV00536194X volume:85 year:2015 pages:21-28 extent:8 https://doi.org/10.1016/j.micpath.2015.05.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.38 Pharmakologie VZ AR 85 2015 21-28 8 045F 610 |
| language |
English |
| source |
Enthalten in Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling Amsterdam [u.a.] volume:85 year:2015 pages:21-28 extent:8 |
| sourceStr |
Enthalten in Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling Amsterdam [u.a.] volume:85 year:2015 pages:21-28 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Pharmakologie |
| institution |
findex.gbv.de |
| topic_facet |
Adenosine Toxicity Trypanosomiasis Cordycepin Pentostatin |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling |
| authorswithroles_txt_mv |
Dalla Rosa, Luciana @@aut@@ Da Silva, Aleksandro S. @@oth@@ Oliveira, Camila B. @@oth@@ Gressler, Lucas T. @@oth@@ Arnold, Caroline B. @@oth@@ Baldissera, Matheus D. @@oth@@ Sagrillo, Michele @@oth@@ Sangoi, Manuela @@oth@@ Moresco, Rafael @@oth@@ Mendes, Ricardo E. @@oth@@ Weiss, Paulo E. @@oth@@ Miletti, Luiz C. @@oth@@ Monteiro, Silvia G. @@oth@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
ELV00536194X |
| dewey-sort |
3610 |
| id |
ELV023724099 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV023724099</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625141635.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.micpath.2015.05.005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015014000005.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV023724099</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0882-4010(15)00086-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">PHARM</subfield><subfield code="q">DE-84</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.38</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dalla Rosa, Luciana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Dose finding of 3′deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adenosine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Toxicity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Trypanosomiasis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cordycepin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pentostatin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Da Silva, Aleksandro S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oliveira, Camila B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gressler, Lucas T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arnold, Caroline B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Baldissera, Matheus D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sagrillo, Michele</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sangoi, Manuela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moresco, Rafael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mendes, Ricardo E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weiss, Paulo E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miletti, Luiz C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Monteiro, Silvia G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Samra, Yara A. ELSEVIER</subfield><subfield code="t">Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00536194X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:85</subfield><subfield code="g">year:2015</subfield><subfield code="g">pages:21-28</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.micpath.2015.05.005</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-PHARM</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.38</subfield><subfield code="j">Pharmakologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">85</subfield><subfield code="j">2015</subfield><subfield code="h">21-28</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Dalla Rosa, Luciana |
| spellingShingle |
Dalla Rosa, Luciana ddc 610 fid PHARM bkl 44.38 Elsevier Adenosine Elsevier Toxicity Elsevier Trypanosomiasis Elsevier Cordycepin Elsevier Pentostatin Dose finding of 3′deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose |
| authorStr |
Dalla Rosa, Luciana |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV00536194X |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ PHARM DE-84 fid 44.38 bkl Dose finding of 3′deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose Adenosine Elsevier Toxicity Elsevier Trypanosomiasis Elsevier Cordycepin Elsevier Pentostatin Elsevier |
| topic |
ddc 610 fid PHARM bkl 44.38 Elsevier Adenosine Elsevier Toxicity Elsevier Trypanosomiasis Elsevier Cordycepin Elsevier Pentostatin |
| topic_unstemmed |
ddc 610 fid PHARM bkl 44.38 Elsevier Adenosine Elsevier Toxicity Elsevier Trypanosomiasis Elsevier Cordycepin Elsevier Pentostatin |
| topic_browse |
ddc 610 fid PHARM bkl 44.38 Elsevier Adenosine Elsevier Toxicity Elsevier Trypanosomiasis Elsevier Cordycepin Elsevier Pentostatin |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s a s d sas sasd c b o cb cbo l t g lt ltg c b a cb cba m d b md mdb m s ms m s ms r m rm r e m re rem p e w pe pew l c m lc lcm s g m sg sgm |
| hierarchy_parent_title |
Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling |
| hierarchy_parent_id |
ELV00536194X |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV00536194X |
| title |
Dose finding of 3′deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose |
| ctrlnum |
(DE-627)ELV023724099 (ELSEVIER)S0882-4010(15)00086-8 |
| title_full |
Dose finding of 3′deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose |
| author_sort |
Dalla Rosa, Luciana |
| journal |
Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling |
| journalStr |
Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
zzz |
| container_start_page |
21 |
| author_browse |
Dalla Rosa, Luciana |
| container_volume |
85 |
| physical |
8 |
| class |
610 610 DE-600 610 VZ PHARM DE-84 fid 44.38 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Dalla Rosa, Luciana |
| doi_str_mv |
10.1016/j.micpath.2015.05.005 |
| dewey-full |
610 |
| title_sort |
dose finding of 3′deoxyadenosine and deoxycoformycin for the treatment of trypanosoma evansi infection: an effective and nontoxic dose |
| title_auth |
Dose finding of 3′deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose |
| abstract |
The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model. |
| abstractGer |
The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model. |
| abstract_unstemmed |
The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA |
| title_short |
Dose finding of 3′deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose |
| url |
https://doi.org/10.1016/j.micpath.2015.05.005 |
| remote_bool |
true |
| author2 |
Da Silva, Aleksandro S. Oliveira, Camila B. Gressler, Lucas T. Arnold, Caroline B. Baldissera, Matheus D. Sagrillo, Michele Sangoi, Manuela Moresco, Rafael Mendes, Ricardo E. Weiss, Paulo E. Miletti, Luiz C. Monteiro, Silvia G. |
| author2Str |
Da Silva, Aleksandro S. Oliveira, Camila B. Gressler, Lucas T. Arnold, Caroline B. Baldissera, Matheus D. Sagrillo, Michele Sangoi, Manuela Moresco, Rafael Mendes, Ricardo E. Weiss, Paulo E. Miletti, Luiz C. Monteiro, Silvia G. |
| ppnlink |
ELV00536194X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.micpath.2015.05.005 |
| up_date |
2024-07-06T19:34:50.477Z |
| _version_ |
1803859515646410752 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV023724099</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625141635.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.micpath.2015.05.005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015014000005.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV023724099</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0882-4010(15)00086-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">PHARM</subfield><subfield code="q">DE-84</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.38</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dalla Rosa, Luciana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Dose finding of 3′deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The aim of this study was to evaluate the therapeutic efficacy and safety of using 3′deoxyadenosine (Cordycepin – adenosine analogue) combined with deoxycoformycin (Pentostatin – an adenosine deaminase inhibitor) in mice infected with Trypanosoma evansi. We show that the combination of Cordycepin (2.0 mg kg−1) and Pentostatin (0.2, 0.5, 1.0, 2.0 mg kg1) is effective in the clearance of T. evansi, although at the higher concentrations of Pentostatin 2 mg kg−1 some toxicity was observed in the liver and kidney. Since the Cordycepin 2.0 mg kg−1 and Pentostatin 0.2 mg kg−1 combination was effective and had low toxicity, we recommend this as a therapeutic option for a T. evansi mouse model.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adenosine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Toxicity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Trypanosomiasis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cordycepin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pentostatin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Da Silva, Aleksandro S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oliveira, Camila B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gressler, Lucas T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arnold, Caroline B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Baldissera, Matheus D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sagrillo, Michele</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sangoi, Manuela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moresco, Rafael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mendes, Ricardo E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weiss, Paulo E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miletti, Luiz C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Monteiro, Silvia G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Samra, Yara A. ELSEVIER</subfield><subfield code="t">Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00536194X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:85</subfield><subfield code="g">year:2015</subfield><subfield code="g">pages:21-28</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.micpath.2015.05.005</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-PHARM</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.38</subfield><subfield code="j">Pharmakologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">85</subfield><subfield code="j">2015</subfield><subfield code="h">21-28</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.400943 |